Humuline Nph Cartridge

Humuline NPH Cartridge is a prescription insulin product that contains recombinant human insulin (rDNA) formulated as an intermediate‑acting preparation. It is supplied in a cartridge compatible with insulin pens for subcutaneous administration. The formulation provides a consistent supply of insulin to help manage blood glucose levels in patients with diabetes. It is marketed in the European Union and requires a healthcare professional’s prescription for proper use.

Humuline NPH Cartridge is indicated for the long‑term management of blood glucose in adults and children with diabetes.

- As part of a basal insulin regimen for type 1 diabetes mellitus, providing steady insulin levels between meals and overnight. - In combination with rapid‑acting insulin analogues for intensive insulin therapy in type 2 diabetes mellitus. - To replace or supplement endogenous insulin in patients with pancreatic insufficiency or after pancreatectomy. - For use in insulin‑treated patients who require a predictable intermediate‑acting insulin profile. - As a component of a structured diabetes self‑management plan under medical supervision.

Adverse reactions to Humuline NPH Cartridge may vary in frequency and severity.

Common: - Mild to moderate hypoglycemia, especially if meals are delayed, carbohydrate intake is reduced, or physical activity is increased. - Localized redness, swelling, tenderness, or itching at the injection site, usually resolving within a few days. - Lipodystrophy presenting as small lumps, thickened skin, or indentations under the skin at repeated injection sites. - Transient weight gain, often modest, associated with improved glycemic control and fluid retention.

Serious: - Severe hypoglycemia with neuroglycopenic symptoms such as confusion, visual disturbances, seizures, or loss of consciousness. - Allergic reactions ranging from mild urticaria and rash to life‑threatening anaphylaxis, requiring immediate medical attention. - Persistent peripheral edema or worsening heart failure symptoms in patients with pre‑existing cardiac disease.

When prescribing Humuline NPH Cartridge, clinicians should consider several precautionary measures to ensure safe use.

- Assess renal and hepatic function, as impairment may alter insulin clearance and increase hypoglycemia risk. - Monitor blood glucose closely during initiation, dose adjustments, and periods of illness or stress. - Educate patients on proper injection technique and rotation of sites to minimize lipodystrophy. - Use caution in pregnant or breastfeeding women; benefits should be weighed against potential risks. - Review concomitant medications that can potentiate hypoglycemia, such as sulfonylureas or meglitinides. - Advise patients to carry rapid‑acting glucose sources in case of unexpected hypoglycemia.

Humuline NPH Cartridge can interact with other agents that affect blood glucose or insulin metabolism.

Avoid: - Concurrent use of other insulin products or high‑dose sulfonylureas, which may cause severe hypoglycemia. - Beta‑blockers that mask hypoglycemia symptoms, making detection more difficult.

Use with caution: - Corticosteroids, which can increase insulin resistance and require dose adjustments. - Thiazide diuretics, which may raise blood glucose levels. - Alcohol consumption, especially in excess, as it can cause unpredictable glucose fluctuations. - ACE inhibitors or ARBs, which generally have minimal effect but may require monitoring of renal function and glucose. - Beta‑agonists (e.g., albuterol) used for asthma, which can transiently raise blood glucose.